What exactly is a mood stabilizer?

Journal of Psychiatry and Neuroscience

Volumn 29, Issue 2, 2004, Pages 87-88

  Young, L Trevor ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CLOZAPINE; GABAPENTIN; LAMOTRIGINE; LITHIUM CARBONATE; MOOD STABILIZER; OLANZAPINE; PSYCHOTROPIC AGENT; TOPIRAMATE; TRANQUILIZER; UNCLASSIFIED DRUG; VALPROIC ACID;

BIPOLAR DEPRESSION; BIPOLAR DISORDER; CLINICAL TRIAL; DRUG CHOICE; DRUG RESPONSE; EDITORIAL; HUMAN; MOOD DISORDER; NEUROPROTECTION; PATIENT SELECTION; PRESCRIPTION; PROPHYLAXIS; SUICIDAL BEHAVIOR; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; ANTIMANIC AGENTS; HUMANS; MOOD DISORDERS;

EID: 2342616086     PISSN: 11804882     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (9)

1. Geddes JR, Burgess S, Hawton K, Jamison K, Goodwin GM. Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Am J Psychiatry 2004;161(2):217-22.
2. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002;159(4 Suppl):1-50.
3. Bauer MS, Mitchner L. What is a "mood stabilizer"? An evidence-based response. Am J Psychiatry 2004;161(1):3-18.
4. Muller-Oerlinghausen B, Berghofer A, Ahrens B. The antisuicidal and mortality-reducing effect of lithium prophylaxis: consequences for guidelines in clinical psychiatry. Can J Psychiatry 2003;48(7):433-9.
5. Tohen M, Ketter TA, Zarate CA, Suppes T, Frye M, Altshuler L, et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry 2003;160(7):1263-71.
6. Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003;60(11):1079-88.
7. Suppes T, Webb A, Paul B, Carmody T, Kraemer H, Rush AJ. Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania. Am J Psychiatry 1999;156(8):1164-9.
8. Coyle JT, Duman RS. Finding the intracellular signaling pathways affected by mood disorder treatments. Neuron 2003;38(2):157-60.
9. Wei Z, Mousseau DD, Richardson JS, Dyck LE, Li XM. Atypical antipsychotics attenuate neurotoxicity of beta-amyloid(25-35) by modulating Bax and Bcl-X(1/s) expression and localization. J Neurosci Res 2003;74(6):942-7.